Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Quarterly Statistics, Q1 2010

This article was originally published in Start Up

Executive Summary

Highlights from the Q1 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $331 million, a 66% drop from the previous quarter's $976 million, and a 52% slide from Q1 2009. As was the case in Q4 2009, Series B rounds dominated in the biopharma and device sectors. Just one acquisition closed in the quarter - BioMarin buying LEAD Therapeutics - however two others are in the works. On the alliance front, SpePharm and Dicerna each signed two deals in Q1.

You may also be interested in...

J&J/Ethicon Endo-Surgery Weighs Breast Care Divestiture To Devicor

Devicor Medical Products is seeking a foothold in the device market with its proposed acquisition of Johnson & Johnson/Ethicon Endo-Surgery's breast care business, the company announced March 30

GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics

Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.

Venture-Backed Dicerna Cuts First Pharma Deal With Kyowa Hakko Kirin As Prelude to 'B' Round

As it looks for a new investor to lead its second round of funding, RNA interference start-up Dicerna Pharmaceuticals has signed its first big-pharma customer. Japan's Kyowa Hakko Kirin will pay $4 million up-front and as much as $120 million in milestones to develop therapeutics around an undisclosed solid-tumor cancer target using Dicerna's technology

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts